Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C S Fuchs

Showing results (41-50 of 57) with videos related to

Pageof 6
Sort By:
Nutrition & Diabetes|June 16, 2015
Impact of vitamin D supplementation on adiposity in African-AmericansP D Chandler, J B Scott, B F Drake, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 8, 2007
Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastatic colorectal cancerJ A Meyerhardt, K Stuart, C S Fuchs, et al.
Endocrine-Related Cancer|April 11, 2013
A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumorsJ R Strosberg, J A Chan, D P Ryan, et al.
British Journal of Cancer|May 30, 2007
Circulating insulin-like growth factor axis and the risk of pancreatic cancer in four prospective cohortsB M Wolpin, D S Michaud, E L Giovannucci, et al.
ESMO Open|August 9, 2021
Quality of life with first-line pembrolizumab for PD-L1-positive advanced gastric/gastroesophageal junction adenocarcinoma: results from the randomised phase III KEYNOTE-062 studyE Van Cutsem, A Valderrama, Y-J Bang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 14, 2009
Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancerP C Enzinger, D P Ryan, J W Clark, et al.
British Journal of Cancer|July 16, 2009
Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancerJ Souglakos, J Philips, R Wang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 16, 2012
A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancerH L Kindler, D A Richards, L E Garbo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 11, 2011
A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinomaJ A Chan, L S Blaszkowsky, P C Enzinger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 3, 2021
Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinomaK Shitara, M Özgüroğlu, Y-J Bang, et al.
Pageof 6

Showing results (41-50 of 57) with videos related to

Sort By:
Pageof 6
Nutrition & Diabetes|June 16, 2015
Impact of vitamin D supplementation on adiposity in African-AmericansP D Chandler, J B Scott, B F Drake, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 8, 2007
Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastatic colorectal cancerJ A Meyerhardt, K Stuart, C S Fuchs, et al.
Endocrine-Related Cancer|April 11, 2013
A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumorsJ R Strosberg, J A Chan, D P Ryan, et al.
British Journal of Cancer|May 30, 2007
Circulating insulin-like growth factor axis and the risk of pancreatic cancer in four prospective cohortsB M Wolpin, D S Michaud, E L Giovannucci, et al.
ESMO Open|August 9, 2021
Quality of life with first-line pembrolizumab for PD-L1-positive advanced gastric/gastroesophageal junction adenocarcinoma: results from the randomised phase III KEYNOTE-062 studyE Van Cutsem, A Valderrama, Y-J Bang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 14, 2009
Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancerP C Enzinger, D P Ryan, J W Clark, et al.
British Journal of Cancer|July 16, 2009
Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancerJ Souglakos, J Philips, R Wang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 16, 2012
A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancerH L Kindler, D A Richards, L E Garbo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 11, 2011
A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinomaJ A Chan, L S Blaszkowsky, P C Enzinger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 3, 2021
Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinomaK Shitara, M Özgüroğlu, Y-J Bang, et al.
Pageof 6